Search Results - oncology+immunotherapy

18 Results

Sort By:

Inhibition of BMI1 Eliminated Cancer Stem Cells and Activates Antitumor Immunity (UCLA Case No. 2020-858)

UCLA researchers in the Department of Dentistry discovered that targeting BMI1in head and neck squamous cell carcinoma (HNSCC) may be a viable immune checkpoint to inhibit metastatic tumor growth, and prevent tumor relapse through activation of cell-intrinsic immunity and purging cancer stem cells (CSCs). BACKGROUND: Cancer stem cells are cancer...

Published: 3/6/2024 | Inventor(s): Cun-Yu Wang, Jia Lingfei

Keywords(s): Cancer stem cells, Epigenetics, Immunooncology, Oncology Immunotherapy, Tumor

Category(s): Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Gene Therapy And Editing

2021-008 TARGETED NEOANTIGEN VACCINATION IN H3G34R/V GLIOMA

UCLA researchers in the Departments of Neurosurgery and Microbiology, Immunology, and Molecular Genetics have developed an immunotherapy treatment methodology for H3G34R/V high-grade glioma, providing an ability to be adapted toward a wide range of similar tumors.BACKGROUND:Over 3000 gliomas and other forms of brain cancer are diagnosed in children...

Published: 7/19/2023 | Inventor(s): Anthony Wang, Geoffrey Owens, Yi Xing, Robert Prins, Linda Liau, David Nathanson

Keywords(s): Immunotherapy, Oncology, Oncology Immunotherapy

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2019-726 AUGMENTATING T-CELL ACTIVATION BY OSCILLATORY FORCES AND ENGINEERED ANTIGEN-PRESENTING CELLS

UCLA researchers in the Department of Pediatrics have developed a suite of novel spherical aAPCs of varying sizes and densities, that can be coupled with an oscillatory stimulus to promote efficient T cell activation: offering the possibility to aptly engineer T cells for a variety of clinical and experimental needs. BACKGROUND:T cells circulate throughout...

Published: 9/5/2023 | Inventor(s): Manish Butte, Fatemeh Sadat Majedi

Keywords(s): Immunology, Immunotherapy, Life Science Research Tools, Oncology, Oncology Immunotherapy

Category(s): Life Science Research Tools > Antibodies, Life Science Research Tools > Research Methods, Diagnostic Markers > Immunology, Therapeutics > Oncology > Oncology Immunotherapy

2019-880 ZIKA VIRUS-BASED ONCOLYTIC THERAPY FOR BRAIN CANCER

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed a novel zika virus-based oncolytic therapy to treat brain cancer.BACKGROUND: Glioma is a type of brain tumor that accounts for 80% of all primary malignant brain tumors. Standard therapy for high-grade glioma requires a combination of surgical resection, radiation...

Published: 9/12/2023 | Inventor(s): Vaithilingaraja Arumugaswami, David Nathanson

Keywords(s): Cns, Drug Delivery, Gene Editing Systems, Gene Therapy, Immunology, Immunotherapy, Oncology, Oncology Immunotherapy, Plasmids / Vectors, Therapeutics & Vaccines, Viral Delivery Systems

Category(s): Diagnostic Markers > Immunology, Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Gene Therapy And Editing, Therapeutics > Oncology > Oncology Immunotherapy

2015-341 COMBINATIONS OF CHECKPOINT INHIBITORS AND DENDRITIC CELL VACCINES TO TREAT BRAIN CANCER

UCLA researchers in the Departments of Neurosurgery and Molecular and Medical Pharmacology have developed an autologous dendritic cell (DC) vaccine in combination with checkpoint inhibitors for the treatment of malignant brain tumors.BACKGROUND: Checkpoint inhibitor therapies, which unblock an existing immune response, or unblock the initiation of an...

Published: 7/19/2023 | Inventor(s): Robert Prins, Linda Liau

Keywords(s): Antibodies, Drug Delivery, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), Oncology Immunotherapy, Therapeutics & Vaccines, Vaccines

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2020-178 COLD ATMOSPHERIC PLASMA TREATMENT FOR CANCER IMMUNOTHERAPY

UCLA researchers in the Department of Bioengineering have developed a novel cancer treatment using a combination of microneedle patch-assisted cold atmospheric plasma and checkpoint blockade.BACKGROUND: Immunotherapy revolutionizes cancer treatment by harnessing the power of the immune system for fighting cancer. Among all immunotherapeutic strategies,...

Published: 7/19/2023 | Inventor(s): Zhen Gu, Richard Wirz, Guojun Chen, Zhitong Chen

Keywords(s): Medical Devices and Materials, Oncology, Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

Gene Modified Autologous Dendritic Cells in Combination with Anti-PD1 Therapy for Metastatic Lung Cancer (UCLA Case No. 2019-844)

UCLA researchers at David Geffen School of Medicine have developed a novel approach of in situ vaccination by intratumorally injecting chemokine gene-modified dendritic cells to sensitize non-responsive non-small cell lung cancer (NSCLC) to anti-PD-1/PD-L1 immunotherapy. BACKGROUND:The treatment of non-small cell lung cancer (NSCLC) has...

Published: 4/9/2024 | Inventor(s): Steven Dubinett

Keywords(s): Drug Delivery, Gene Editing Systems, Gene Therapy, Immunotherapy, Medical Devices and Materials, Oncology, Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

2016-255 Method to Enrich for Cells Transduced with Chimeric Antigen Receptors for Gene Therapy (2016-051 rolled in)

Method to Enrich for Cells Transduced with Chimeric Antigen ReceptorsSUMMARYResearchers at UCLA have developed a method to expand chimeric antigen receptor-transduced T cells for use in immunotherapies.BACKGROUNDChimeric Antigen Receptors (CAR) T cells are promising therapeutics for the treatment of cancer and are also being considered for the treatment...

Published: 2/14/2024 | Inventor(s): Otto Yang, Jerome Zack, Scott Kitchen, Ayub Ali, Hwee Ng, Irvin S.Y. Chen

Keywords(s): Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy

2019-008 COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES

Researchers at the UCLA Department of Microbiology, Immunology, and Molecular Genetics have isolated T cell receptors (TCRs) specific for NY-ESO-1 epitopes presented by four MHC molecules, and developed novel approaches to extend TCR gene therapies targeting NY-ESO-1 using these TCRs.BACKGROUNDThe αβ T cell receptor (TCR) determines the unique...

Published: 7/19/2023 | Inventor(s): Owen Witte, Jami Witte, Michael Bethune, Antoni Ribas, Lili Yang, Jonathan Cebon, Katherine Woods, Ashley Knights

Keywords(s): Immunotherapy, Life Science Research Tools, Oncology, Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Therapeutics, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

IL-6 Receptor Alpha-Binding Protein and its Use In Controlling Cytokine Release Syndrome In Immunotherapy (UCLA Case No. 2017-453)

SUMMARY UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a novel protein that binds to and inhibits human IL-6 receptor alpha (IL-6Rα), which can be used to modulate and/or prevent cytokine release syndrome in immunotherapy. BACKGROUND Severe cytokine release syndrome (CRS), or a sudden and dramatic...

Published: 8/31/2023 | Inventor(s): Yvonne Chen, Meng-Yin Lin

Keywords(s): Immunotherapy, Life Science Research Tools, Oncology Immunotherapy

Category(s): Life Science Research Tools, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

1 2